ÃÖ±Ù ¾ð·Ð¿¡ ginsenoside Rg3¿¡ ÀÇÇØ ½ÉÇ÷°üÁúȯÀÌ À¯¹ßµÉ ¼ö ÀÖ´Ù´Â ¿¬±¸ ³í¹®ÀÌ ¹ßÇ¥µÈ ÈÄ Àü¼º¿¡ ´ëÇØ ³í¶õÀÌ ÀϾ°í ÀÖ¾î¼ ÀÌ¿¡ ÀÇÇØ ½ÉÇ÷°üÁúȯÀÌ À¯¹ßµÉ ¼ö ÀÖ´Ù´Â ³í¶õ¿¡ ´ëÇØ µ¿¼ºñ±³ÇÑÀÇÇÐȸ ±è¿ë¼ö ȸÀåÀÇ ¼Ò°ßÀ» °ÔÀçÇß´Ù.
2010³â¿¡ ¹ßÇ¥µÈ ¼¿ï´ë ¾à´ë Á¤ÁøÈ£ ±³¼öÀÇ ³í¹® ‘Vascular smooth muscle dysfunction and remodeling induced by ginsenoside Rg3, a bioactive component of ginseng’(Toxicological Sciences, Volume 117, Issue 2, 1 October 2010, Pages 505–514)¿¡¼´Â Á¤»ó Áã¿¡°Ô Rg3(20mg/kg)¸¦ Á¤¸ÆÅõ¿©·Î ÀÏÁÖÀÏ¿¡ 5ÀÏ 5ml¿¡ ³ì¿© 4ÁÖ°£ Á¤¸ÆÁÖ»çÇÑ °á°ú, Á÷°æÀÌ Áõ°¡ÇÏ°í µ¿¸Æº® µÎ²²°¡ ¾ã¾ÆÁ®¼ ÈäºÎ´ëµ¿¸ÆÀÇ ÆØâÀ» ÃÊ·¡ÇÑ´Ù°í ¹ßÇ¥Çß´Ù. Áï Rg3ÀÇ ¹Ýº¹»ç¿ëÀÌ Ç÷°ü±¸Á¶ÀÇ ¿µ¼ÓÀû º¯È¸¦ °¡Á®¿Ã ¼ö ÀÖ´Ù°í ÁÖÀåÇÑ´Ù. ¶ÇÇÑ 2016³â¿¡ ¹ßÇ¥ÇÑ ¼®»ç³í¹® ‘Ginsenoside Rg3¿¡ ÀÇÇÑ Ç÷°ü ÆòÈ°±Ù¼¼Æ÷°ñ°Ý ºØ±«¿¡ µû¸¥ ¼öÃà±â´É ¼Õ»ó ¹× Apoptosis ±âÀü¿¡ °üÇÑ ¿¬±¸’(Á¤¿¹·Ã, ¼®»çÇÐÀ§³í¹® ¼¿ï´ëÇб³ ´ëÇпø : ¾àÇдëÇÐ ¾àÇаú ¿¹¹æ¾àÇÐÀü°ø,)¿¡¼´Â ³¿ë¼º ¹°ÁúÀÎ Rg3¸¦ DMSO(À¯ÈÁ¦)¿¡ ³ì¿© ½ÇÇèÇÑ °á°ú, Rg3°¡ ¾Ï¼¼Æ÷¿Í Á¤»ó ÆòÈ°±Ù¼¼Æ÷¿¡¼ µ¿ÀÏÇÑ ¼¼Æ÷»ç¸êÀ» À¯µµÇÑ´Ù°í ¹ßÇ¥Çß´Ù.
ÀÌ´Â Çö½Ç¼º ¾ø´Â ½ÇÇè¿ë·®ÀÌ ¹®Á¦´Ù.
Sigma &Aldrich Rg3 Toxicity ¿¡ ÀÇÇÏ¸é “Rg3ÀÇ ¼¼Æ÷ µ¶¼ºÀº 20uMÀ¸·ÎºÎÅÍ ³ªÅ¸³´Ù.”°í ±â¼úÇÏ°í Àִµ¥ Rg3ÀÇ ºÐÀÚ·®(Molecular weight)Àº 785À̹ǷΠÀ̸¦ ml ³óµµ·Î ȯ»êÇØ º¸¸é 15.7μg/mlºÎÅÍ ¼¼Æ÷µ¶¼ºÀÌ ¹ßÇöµÈ´Ù ÇÒ ¼ö ÀÖ´Ù.
Liu JPµîÀÇ ‘Toxicity of a novel anti-tumor agent 20(S)-ginsenoside Rg3: a 26-week intramuscular repeated administration study in rats.’ (Food Chem Toxicol, 2012, Oct;50(10);3388-96)¿¡´Â RG3¸¦ Ç×¾ÏÁ¦·Î¼ ¼·ÃëÇÒ ¶§, Kg´ç 1ÀÏ 4.2mg/kg/day¸¦ ¾ÈÀü ¼·Ãë·®À¸·Î ¼³Á¤ÇÏ°í ÀÖ´Ù. 60kg »ç¶÷ ±âÁØÀ¸·Î ÇÏ·ç Rg3 252mg, È«»ï±âÁØÀ¸·Î ÇÏ·ç 82gÀÌÇϸ¦ º¹¿ëÇÏ¸é ¾ÈÀüÇÏ´Ù´Â ±âÁØÀ» Á¦½ÃÇÏ°í ÀÖ´Ù.
±âÁ¸ Rg3 µ¶¼º¿¬±¸¿Í µÎ ÆíÀÇ ¿¬±¸ ³í¹®À» ºñ±³Çغ¸¸é Á¤ ±³¼ö°¡ ½ÇÇè¿¡ »ç¿ëÇÑ Rg3(20mg/1kg) ±âÁØÀ¸·Î Rg3¸¦ Á¤¸Æ ÁÖÀÔÇÏ¸é ¼¼Æ÷µ¶¼ºÀÌ ÀϾٰí Çߴµ¥, µ¶¼ºÀÌ ÀϾ´Â 15.7μg/ml ÀÌ»óÀÇ °í¿ë·®À» ÁÖÀÔÇÏ´Â °ÍÀ̱⠶§¹®¿¡ µ¶¼ºÀÌ ÀϾÁö ¾Ê´Â °ÍÀÌ ÀÌ»óÇÑ ÀÏÀÌ´Ù.
25gÀÇ Áã¿¡ Åõ¿©ÇÑ´Ù¸é 500μgÀ» 5ml¿¡ Èñ¼®ÇØ Åõ¿©ÇÏ´Â °ÍÀε¥, µ¶¼ºÀÌ ³ªÅ¸³ª´Â ¿ë·®ÀÇ 6¹è¸¦ 4ÁÖ°£ Åõ¿©Çϱ⠶§¹®¿¡ ´ç¿¬È÷ ¼¼Æ÷µ¶¼ºÀÌ ÀϾ°Ô µÈ´Ù.
Rg3(20mg/1kg) ±âÁØÀ» 60kg »ç¶÷¿¡°Ô Àû¿ëÇϸé Rg3 Ç÷Áß³óµµ°¡ 1200mgÀÌ µÈ´Ù. È«»ï 1g¿¡ ÃÖ´ë 3mgÀÇ Rg3°¡ ÀÖ°í Rg3ÀÇ Èí¼öÀ²À» ÃÖ´ë 3%·Î °¡Á¤ÇÏ¸é °æ±¸Åõ¿©·Î Ç÷Áß³óµµ 1200mgÀ» À¯ÁöÇÏ°íÀÚ ÇÒ ¶§, È«»ïÀ» ÇÑ ¹ø¿¡ 14kg¾¿, 4ÁÖ°£ Åõ¿©ÇØ¾ß ½ÉÇ÷°üÁúȯÀÌ À¯¹ßµÈ´Ù´Â À̾߱Ⱑ µÈ´Ù. Çö½Ç¼ºÀÌ ¾ø´Â ½ÇÇè³óµµÀÎ °ÍÀÌ´Ù.
2016³â¿¡ ¹ßÇ¥µÈ ¼®»ç³í¹®¿¡¼µµ ¼¼Æ÷ÁÖ ½ÇÇè¿¡ ¼³Á¤µÈ 10μM³óµµ¸¦ ml·Î ȯ»êÇغ¸¸é 7.85μg/ml À̸ç 60kg »ç¶÷ Ç÷Áß³óµµ 40mg Á¤µµ¿¡ ÇØ´çÇÑ´Ù. Áï, È«»ïÀ» Çѹø¿¡ 500gÀ» º¹¿ëÇØ¾ß ÇÏ°í, µ¶¼ºÀÌ ½ÉÇÏ°Ô ³ªÅ¸³ª´Â 25μMÀ» ±âÁØÀ¸·Î ÇÑ´Ù¸é ¼ºÀÎ 60kg ±âÁØÀ¸·Î Ç÷Áß³óµµ 100mgÀÌ´Ï È«»ïÀ» Çѹø¿¡ 1kg ÀÌ»óÀ» º¹¿ëÇØ¾ß ÇÑ´Ù´Â °á·ÐÀÌ ³ª¿Â´Ù. ÀÌ´Â 2012³â¿¡ Liu JP µîÀÌ ¹ßÇ¥ÇÑ ÇÏ·ç ¾ÈÀü¿ë·® 82gÀÇ 12¹è ÀÌ»óÀÇ °í¿ë·®À» º¹¿ëÇÏ´Â °ÍÀÌ¾î¼ µ¶¼ºÀÌ ³ª¿À´Â °ÍÀº ´ç¿¬ÇÑ °á°úÀÌ´Ù.(½ÇÁ¦ °£ÃÊȸÅõ°úÀ² µîÀ» °í·ÁÇϸé È«»ïÀ» 2kg ÀÌ»óÀ» º¹¿ëÇØ¾ß Ç÷Á߳󵵸¦ À¯ÁöÇÒ ¼ö ÀÖ´Ù.)
ÀÌ¿Í °°ÀÌ µÎ ³í¹® ´Ù ¼¼Æ÷µ¶¼ºÀÌ ÀϾ´Â ¿ë·®À» ÃÊ°úÇؼ Åõ¿©ÇßÀ¸´Ï ¼¼Æ÷µ¶¼ºÀÌ ÀϾٴ °á·ÐÀº ½±°Ô ¿¹°ßµÉ ¼ö ÀÖ°í ÀÌ ³í¹®À» ±Ù°Å·Î Rg3°¡ ½ÉÇ÷°ü°è ÁúȯÀ» À¯¹ßÇÑ´Ù´Â °ÍÀº À߸øµÈ ÁÖÀåÀ̸ç, ´Ù¸¥ ³í¹®À» ã¾Æº¸¸é Á¤¹Ý´ëÀÇ ½ÇÇè°á°ú°¡ ¹ßÇ¥µÇ°í ÀÖ´Ù.
³í¹® ‘A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases’ (Chang Ho Lee 1, Jong-Hoon Kim, Journal of Ginseng Research Volume 38, Issue 3, July 2014, Pages 161-166)¿¡¼´Â Rg3°¡ ROS ÇÕ¼º¹æÇØ, NO »ý¼ºÃËÁø, Ç÷¾×¼øȯ °³¼±, Ç÷°ü¿îµ¿ ±äÀå ÁõÁø, Ç÷¼ÒÆÇ ÀÀÁý¹æÇØ, Ca ÀÌ¿Âä³Î Á¶Àý µîÀ¸·Î ½ÉÇ÷°ü À§ÇèÀÎÀÚ¿¡ ±àÁ¤ÀûÀÎ ¾à¸®ÀÛ¿ëÀ» º¸Àδٰí È®ÀÎÇß´Ù.
¶ÇÇÑ ‘Roles and mechanisms of ginsenoside in cardiovascular diseases:progress and perspectives’(Yingying Sun, Yue Liu, Keji Chen, Science China Life Sciences March 2016, Volume 59, Issue 3, pp 292–298)¿¡¼´Â Áø¼¼³ë»çÀ̵尡 µ¿¸Æ°æÈ ¹æÁö ¹× Ç÷°ü³»ÇÇÃþ º¸È£, ºÎÁ¤¸Æ ¹æÁö, ½É±ÙÇãÇ÷ ¿¹¹æ, ½É½ÇÀçÇü¼º ¹æÁöÀÇ 4°¡Áö È¿°ú¸¦ ³ªÅ¸³½´Ù°í ¹ßÇ¥Çß´Ù.
‘Rg3-enriched Korean Red Ginseng improves vascular function in spontaneously hypertensive rats’(Jung-Bum Park, Sun Kwan Kwon, Harsha Nagar, Saet-byel Jung, Byeong Hwa Jeon, Chang Sup Kim, Jin-Hwan Oh, Hee-Jung Song, Cuk-Seong Kim, Journal of Ginseng Research Volume 38, Issue 4, 15 October 2014, Pages 244-250)¿¡¼´Â °íÇ÷¾ÐÁ㠸𵨿¡¼ 6ÁÖ°£ Rg3¸¦ 1.27μM Åõ¿©ÇÑ °á°ú Ç÷°ü±â´É°ú ¸é¿ªÃ¼°è°¡ °³¼±µÇ¾ú´Ù°í ¹àÇû´Ù.
µ¶¼ºÀÌ À¯¹ßµÇÁö ¾Ê´Â Àú³óµµ Rg3¸¦ Åõ¿©ÇÑ °á°ú ½ÉÇ÷°üÁúȯ Ä¡·á¿Í ¿¹¹æ¿¡ È¿°ú°¡ ÀÖ´Ù´Â ³í¹® ¹ßÇ¥¿Í Rg3 µ¶¼ºÀÌ À¯¹ßµÇ´Â 20μM ÀÌ»óÀ» Åõ¿©ÇÏ°í ¼¼Æ÷µ¶¼ºÀÌ À¯¹ßµÉ ¼ö ÀÖ´Ù´Â ³í¹®¹ßÇ¥¸¦ ºñ±³Çϸé Á¤±³¼öÀÇ ÁÖÀåÀº ¼³µæ·ÂÀÌ »ó´çÈ÷ ¶³¾îÁø´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù.
Á¤±³¼ö°¡ Rg3°¡ ½ÉÇ÷°üÁúȯÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù°í ¹ßÇ¥ÇÑ ¿¬±¸ °á°ú´Â µ¶¼ºÀ» À¯¹ßÇÏ´Â ±âÀü¿¬±¸¿¡´Â °¡Ä¡°¡ ÀÖÀ»Áö ¸ô¶óµµ, µ¶¼ºÀ» À¯¹ßÇÏ´Â ±âÁØÄ¡ ÀÌ»óÀÇ °í¿ë·®À» Åõ¿©ÇÏ¿© ½ÉÇ÷°üÁúȯÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù´Â ÁÖÀåÀº ¼³µæ·ÂÀÌ ¶³¾îÁö¸ç, Á¤±³¼öÀÇ ÁÖÀåÀ» ÀÔÁõÇϱâ À§Çؼ´Â ´õ ¸¹Àº ÈÄ¼Ó ¿¬±¸µéÀÌ ÇÊ¿äÇѵ¥µµ ¼º±ÞÇÏ°Ô ¾ð·Ð¿¡ ¿¬±¸ °á°ú¸¦ ¹ßÇ¥ÇÏ¿© ¸¹Àº È¥¶õÀ» ÀÏÀ¸Å² °ÍÀº ÇÐÀڷμ ½ÅÁßÇÏÁö ¸øÇÑ Ã³½ÅÀÌ´Ù.
±è ¿ë ¼ö/µ¿¼ºñ±³ÇÑÀÇÇÐȸ ȸÀå-ÇÑÀÇÇÐ ¹Ú»ç |